By ROBERT CYRAN
Low efficacy, side effects and regulations all threaten to put a crimp in sales of the newly approved libido drug for women.
Published: August 21, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1LnvrhC
from WordPress http://ift.tt/1E8sQFP
via Hadi Aboukhater
No comments:
Post a Comment